What is the primary delivery method for Rivastigmine in patients with gastrointestinal sensitivity?

Rivastigmine is primarily delivered through a transdermal patch for patients who experience gastrointestinal sensitivity. This method is particularly beneficial because it avoids the gastrointestinal tract entirely, which can be problematic for patients who are prone to side effects from oral administration, such as nausea and vomiting. The transdermal patch allows for a steady release of the medication directly into the bloodstream, ensuring effective plasma concentrations while minimizing gastrointestinal side effects. This delivery method enhances patient compliance and tolerability, especially in those who may struggle with oral dosing.

In contrast, other methods such as intravenous infusion and inhalation spray are not commonly used for rivastigmine, and oral tablets can exacerbate gastrointestinal symptoms in sensitive patients.